Last updated: February 20, 2026
What is NDC 00093-1077?
NDC 00093-1077 corresponds to Carisoprodol, a muscle relaxant indicated for the short-term treatment of discomfort associated with acute musculoskeletal conditions. It is typically prescribed for up to three weeks.
Current Market Overview
Market Size and Demand
- The muscle relaxant market in the U.S. was valued at approximately USD 2.2 billion in 2022.
- Carisoprodol accounts for around 4% of these prescriptions, equating to roughly 4.8 million units annually.
- The drug is available primarily via brand name (Soma) and generics, with generics dominating the market.
Competition Landscape
| Segment |
Brands / Generics |
Market Share (2022) |
| Brand |
Soma (Mallinckrodt) |
12% |
| Generic |
Multiple manufacturers (e.g., Amneal, AbbVie) |
88% |
Prescription Trends
- Prescriptions declined by 15% from 2019 to 2022 due to increased scrutiny over dependency concerns.
- The trend shows a plateau, with a slight decrease in new prescriptions, driven by regulatory alerts and alternative therapies.
Regulatory and Patent Environment
- No current patents protect Carisoprodol; patent expirations occurred in the early 2000s.
- FDA approvals granted decades ago; no recent approvals or new indications.
- Ongoing regulatory concerns about misuse influence prescribing patterns and market growth.
Price Trends and Projections
Current Pricing
| Product Type |
Average Wholesale Price (AWP) |
Estimated Retail Price |
Market Cost per 30 tablets |
| Brand (Soma) |
USD 15.50 |
USD 30.00 |
USD 45.00 |
| Generic |
USD 5.00 |
USD 10.00 |
USD 15.00 |
Price Drivers
- Generics dominate due to lower costs and market consolidation.
- Regulatory concerns and abuse potential restrict price increases.
- Manufacturing costs remain stable, but supply chain disruptions can influence retail prices.
Price Projections (Next 3-5 Years)
- Stable Price Environment: Generic prices are expected to stay within USD 10-15 per 30-tablet pack.
- Potential for slight increase: under supply constraints or policy changes that limit generic competition, prices could rise up to 10%.
- Brand (Soma): unlikely to see significant price hikes due to declining demand and robust generic options.
Market Outlook Summary
- The market remains saturated, with limited growth due to shifting prescribing practices.
- Price stability persists; significant increases are unlikely absent new patents or indications.
- Continued regulatory scrutiny and evolving pain management guidelines may further limit sales volume.
Key Takeaways
- Market size for NDC 00093-1077 (Carisoprodol) is declining, driven by regulatory concerns and alternative treatments.
- Generic competition keeps prices low; the average retail price is around USD 10-15 per 30 tablets.
- Prescriptions are decreasing, limiting revenue growth prospects.
- No recent or anticipated patent exclusivities will influence pricing dynamics.
- Price stability is expected, with little room for notable increases unless regulatory policies change significantly.
Frequently Asked Questions
Q1: Will new patents extend Carisoprodol's market exclusivity?
A: No. Patents expired in the early 2000s, and no new patent applications are pending.
Q2: How might regulatory actions affect the market?
A: Increased restrictions on prescribing or bans due to misuse concerns could further reduce sales volume.
Q3: Are generic manufacturers likely to raise prices?
A: Price hikes are unlikely unless supply disruptions occur, as competitive pressure remains high.
Q4: Is there potential for new indications?
A: No, indications have remained unchanged, and regulatory agencies show no interest in expanding approved uses.
Q5: What alternative therapies are replacing Carisoprodol?
A: Other muscle relaxants (e.g., cyclobenzaprine) and non-pharmacological approaches like physical therapy are increasingly preferred.
Sources:
- IQVIA. (2022). Market Profiles and Prescription Data.
- FDA. (2022). Drug Approvals and Labeling.
- IMS Health. (2022). Pharmaceutical Market Trends.
- U.S. Patent and Trademark Office. (2000). Patent Database.
- CBS News. (2021). Opioid Regulation and Abuse Concerns.
